Clinical Significance of Different Profiles of anti-Ro Antibodies in Connective Tissue Diseases

Yang, Hai-Tao1,2; Hong, Xiao-Ping1,2; Guo, Jie-Wen3; Zhong, Xiao-Ling2,4; Liao, Rui3; Liu, Cui-Lian1,2; Liu, Li-Xiong1,2; Li, Kai1,2; Chen, Yu-Lan1,2; Liu, Dong-Zhou1,2

2023-01-25

10.1155/2023/9195157

Journal of Immunology Research   Impact Factor & Quartile

2314-8861

2314-7156

Objective. Anti-Ro60 and anti-Ro52 antibodies are associated with different connective tissue diseases (CTDs). However, the clinical significance of anti-Ro antibodies is not always consistent among different global regions. The aim of this study was to investigate the clinical characteristics of patients with anti-Ro antibodies. Methods. A total of 1596 inpatients with anti-Ro antibodies were included in the study. Demographic, clinical, and serological data were compared between individuals with different profiles of anti-Ro antibodies: patients with anti-Ro52 antibodies alone, patients with anti-Ro60 antibodies alone, and patients with combined anti-Ro52 and anti-Ro60 antibodies. Results. Of the 1596 patients, 1362 (85.3%) were female, the mean age was 45.5 years, and systemic lupus erythematosus (SLE) (46.0%) and Sjogren's syndrome (SS) (19.0%) were the most common CTD diagnoses. Among the patients with anti-Ro52 antibodies alone, idiopathic inflammatory myopathy (18.8%) and SLE (17.6%) were the most common CTD diagnoses. The coexistent autoantibodies of this group were significantly lower compared with those of the other two groups, while the presence of anti-Jo1 antibodies were significantly higher compared with those of the other two groups (3.7% vs. 0.6% vs. 1.9%, p=0.029). In addition, the patients with isolated anti-Ro52 antibodies were more likely to suffer from interstitial lung disease (35.5% vs. 11.3% vs. 13.7%, p < 10-4) and pulmonary arterial hypertension (10.1% vs. 5.3% vs. 3.6%, p=0.001) compared with the other two groups of patients. Compared with patients with isolated anti-Ro52 or anti-Ro60 antibodies, the patients with combined anti-Ro52 and anti-Ro60 antibodies were more likely to suffer from xerophthalmia and xerostomia. Furthermore, hypocomplementemia, hyperglobulinemia, and proteinuria were particularly prevalent in patients with anti-Ro60 antibodies. Conclusion. Different profiles of anti-Ro antibodies were significantly associated with clinical phenotypic features in CTDs, indicating the potential diagnostic and prognostic value of these antibodies in clinical practice.

SCI

English

Corresponding

Shenzhen Science and Technology Innovation Program[JCYJ20190807144418845] ; National Natural Science Foundation of China[81971464] ; National Key Research and Development Program of China[2019YFC0840600]

Immunology

Immunology

WOS:000926161600002

HINDAWI LTD

Web of Science

1.Jinan Univ, Shenzhen Peoples Hosp, Dept Rheumatol & Immunol, Clin Med Coll 2, Shenzhen, Guangdong, Peoples R China
2.Southern Univ Sci & Technol, Affiliated Hosp 1, Shenzhen, Guangdong, Peoples R China
3.Jinan Univ, Shenzhen Peoples Hosp, Clin Med Coll 2, Shenzhen, Guangdong, Peoples R China
4.Jinan Univ, Shenzhen Peoples Hosp, Dept Radiol, Clin Med Coll 2, Shenzhen, Guangdong, Peoples R China

Yang, Hai-Tao,Hong, Xiao-Ping,Guo, Jie-Wen,et al. Clinical Significance of Different Profiles of anti-Ro Antibodies in Connective Tissue Diseases[J]. Journal of Immunology Research,2023,2023.

Yang, Hai-Tao.,Hong, Xiao-Ping.,Guo, Jie-Wen.,Zhong, Xiao-Ling.,Liao, Rui.,...&Liu, Dong-Zhou.(2023).Clinical Significance of Different Profiles of anti-Ro Antibodies in Connective Tissue Diseases.Journal of Immunology Research,2023.

Yang, Hai-Tao,et al."Clinical Significance of Different Profiles of anti-Ro Antibodies in Connective Tissue Diseases".Journal of Immunology Research 2023(2023).